Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.

Walter HS, Rule SA, Dyer MJ, Karlin L, Jones C, Cazin B, Quittet P, Shah N, Hutchinson CV, Honda H, Duffy K, Birkett J, Jamieson V, Courtenay-Luck N, Yoshizawa T, Sharpe J, Ohno T, Abe S, Nishimura A, Cartron G, Morschhauser F, Fegan C, Salles G.

Blood. 2016 Jan 28;127(4):411-9. doi: 10.1182/blood-2015-08-664086. Epub 2015 Nov 5.

2.

Production and binding analyses of a humanised scFv against a cryptic epitope on tumour-associated fibronectin.

Johdi NA, Harman R, Sanjuan I, Kousparou C, Courtenay-Luck N, Deonarain MP.

Protein Expr Purif. 2013 Mar;88(1):157-63. doi: 10.1016/j.pep.2012.12.002. Epub 2013 Jan 3.

PMID:
23291225
3.

Antibody targeting of Cathepsin S induces antibody-dependent cellular cytotoxicity.

Kwok HF, Buick RJ, Kuehn D, Gormley JA, Doherty D, Jaquin TJ, McClurg A, Ward C, Byrne T, Jaworski J, Leung KL, Snoddy P, McAnally C, Burden RE, Gray B, Lowry J, Sermadiras I, Gruszka N, Courtenay-Luck N, Kissenpfennig A, Scott CJ, Johnston JA, Olwill SA.

Mol Cancer. 2011 Dec 14;10:147. doi: 10.1186/1476-4598-10-147.

4.

Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer.

Pegram MD, Borges VF, Ibrahim N, Fuloria J, Shapiro C, Perez S, Wang K, Schaedli Stark F, Courtenay Luck N.

Breast Cancer Res. 2009;11(5):R73. doi: 10.1186/bcr2409.

5.

Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells.

Soundararajan S, Wang L, Sridharan V, Chen W, Courtenay-Luck N, Jones D, Spicer EK, Fernandes DJ.

Mol Pharmacol. 2009 Nov;76(5):984-91. doi: 10.1124/mol.109.055947. Epub 2009 Aug 5.

6.

The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells.

Soundararajan S, Chen W, Spicer EK, Courtenay-Luck N, Fernandes DJ.

Cancer Res. 2008 Apr 1;68(7):2358-65. doi: 10.1158/0008-5472.CAN-07-5723.

7.

Development of ELISAs for quantification of HMFG1-specific human anti-mouse IgG and IgM antibodies.

Oei AL, Boerman OC, Geurts-Moespot A, van Eerd JE, van Tienoven D, Courtenay-Luck N, Thomas CM, Massuger LF, Sweep FC.

Int J Biol Markers. 2007 Jul-Sep;22(3):167-71.

PMID:
17922458
8.

huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models.

Lo KM, Lan Y, Lauder S, Zhang J, Brunkhorst B, Qin G, Verma R, Courtenay-Luck N, Gillies SD.

Cancer Immunol Immunother. 2007 Apr;56(4):447-57. Epub 2006 Jul 28.

PMID:
16874486
9.

Characterisation and internalisation of recombinant humanised HMFG-1 antibodies against MUC1.

Pericleous LM, Richards J, Epenetos AA, Courtenay-Luck N, Deonarain MP.

Br J Cancer. 2005 Nov 28;93(11):1257-66.

10.

Impact of antibody framework residue VH-71 on the stability of a humanised anti-MUC1 scFv and derived immunoenzyme.

Krauss J, Arndt MA, Zhu Z, Newton DL, Vu BK, Choudhry V, Darbha R, Ji X, Courtenay-Luck NS, Deonarain MP, Richards J, Rybak SM.

Br J Cancer. 2004 May 4;90(9):1863-70.

11.

Source of oncofetal ED-B-containing fibronectin: implications of production by both tumor and endothelial cells.

Midulla M, Verma R, Pignatelli M, Ritter MA, Courtenay-Luck NS, George AJ.

Cancer Res. 2000 Jan 1;60(1):164-9.

12.

Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide.

Sivolapenko GB, Skarlos D, Pectasides D, Stathopoulou E, Milonakis A, Sirmalis G, Stuttle A, Courtenay-Luck NS, Konstantinides K, Epenetos AA.

Eur J Nucl Med. 1998 Oct;25(10):1383-9.

PMID:
9818277
13.

Analysis of the kappa light chain variable region in multiple myeloma.

Kosmas C, Viniou NA, Stamatopoulos K, Courtenay-Luck NS, Papadaki T, Kollia P, Paterakis G, Anagnostou D, Yataganas X, Loukopoulos D.

Br J Haematol. 1996 Aug;94(2):306-17.

PMID:
8759891
14.

Structure-function correlation and biostability of antibody CDR-derived peptides as tumour imaging agents.

Hussain R, Courtenay-Luck NS, Siligardi G.

Biomed Pept Proteins Nucleic Acids. 1996-1997;2(3):67-70.

PMID:
9575342
15.

Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody.

Sivolapenko GB, Douli V, Pectasides D, Skarlos D, Sirmalis G, Hussain R, Cook J, Courtenay-Luck NS, Merkouri E, Konstantinides K, et al.

Lancet. 1995 Dec 23-30;346(8991-8992):1662-6.

PMID:
8551823
16.

Generation of monoclonal antibodies utilizing the host anti-idiotypic network.

Hatzistilianou MN, Sivolapenko GB, Courtenay-Luck NS, Epenetos AA, Ritter MA.

In Vivo. 1995 Mar-Apr;9(2):139-44.

PMID:
7548789
17.

Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer.

Kosmas C, Epenetos AA, Courtenay-Luck NS.

Cancer. 1994 Jun 15;73(12):3000-10.

19.

Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy.

Kosmas C, Snook D, Gooden CS, Courtenay-Luck NS, McCall MJ, Meares CF, Epenetos AA.

Cancer Res. 1992 Feb 15;52(4):904-11.

21.

Immunolocalisation of testicular tumours using radiolabelled monoclonal antibody to placental alkaline phosphatase.

Kalofonos HP, Kosmas C, Pawlikowska TR, Bamias A, Snook D, Dhokia B, Sivolapenko GB, Courtenay-Luck NS, Epenetos AA.

J Nucl Med Allied Sci. 1990 Oct-Dec;34(4):294-8.

PMID:
2090793
22.
23.

Diversity of the human immune response to clinically used murine monoclonal antibodies.

Courtenay-Luck NS, Epenetos AA.

Cancer Treat Res. 1990;51:353-62. Review. No abstract available.

PMID:
1977455
24.

Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase.

Kalofonos HP, Pawlikowska TR, Hemingway A, Courtenay-Luck N, Dhokia B, Snook D, Sivolapenko GB, Hooker GR, McKenzie CG, Lavender PJ, et al.

J Nucl Med. 1989 Oct;30(10):1636-45.

25.

Intraperitoneal radioimmunotherapy for ovarian cancer: pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies.

Stewart JS, Hird V, Snook D, Sullivan M, Hooker G, Courtenay-Luck N, Sivolapenko G, Griffiths M, Myers MJ, Lambert HE, et al.

Int J Radiat Oncol Biol Phys. 1989 Feb;16(2):405-13.

PMID:
2921145
26.

Targeting of monoclonal antibodies to tumours.

Courtenay-Luck NS, Epenetos AA.

Curr Opin Immunol. 1989-1990;2(6):880-3. Review. No abstract available.

PMID:
2486568
27.

Development of anti-idiotypic antibodies against tumour antigens and autoantigens in ovarian cancer patients treated intraperitoneally with mouse monoclonal antibodies.

Courtenay-Luck NS, Epenetos AA, Sivolapenko GB, Larche M, Barkans JR, Ritter MA.

Lancet. 1988 Oct 15;2(8616):894-7.

PMID:
2902328
28.

Antibody guided targeting of non-small cell lung cancer using 111In-labeled HMFG1 F(ab')2 fragments.

Kalofonos HP, Sivolapenko GB, Courtenay-Luck NS, Snook DE, Hooker GR, Winter R, McKenzie CG, Taylor-Papadimitriou JJ, Lavender PJ, Epenetos AA.

Cancer Res. 1988 Apr 1;48(7):1977-84.

29.

Antibody-guided irradiation of hepatic metastases using intrahepatically administered radiolabelled anti-CEA antibodies with simultaneous and reversible hepatic blood flow stasis using biodegradable starch microspheres.

Epenetos AA, Courtenay-Luck N, Dhokia B, Snook D, Hooker G, Lavender JP, Hemmingway A, Carr D, Paraharalambous M, Bosslet K.

Nucl Med Commun. 1987 Dec;8(12):1047-58.

PMID:
3449789
30.

Preexisting human anti-murine immunoglobulin reactivity due to polyclonal rheumatoid factors.

Courtenay-Luck NS, Epenetos AA, Winearls CG, Ritter MA.

Cancer Res. 1987 Aug 15;47(16):4520-5.

31.

Intraperitoneal administration of an I125 labelled monoclonal antibody for localization of human colorectal cancer in the nude mouse.

Shihab F, Azar HA, Finney R, Tyson IB, Tenorio LE, Courtenay-Luck N, Epenetos AA, Hadden JW.

Int J Immunopharmacol. 1987;9(7):783-92.

PMID:
2828253
32.

Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms.

Courtenay-Luck NS, Epenetos AA, Moore R, Larche M, Pectasides D, Dhokia B, Ritter MA.

Cancer Res. 1986 Dec;46(12 Pt 1):6489-93.

33.

Antibody-guided irradiation of malignant pleural and pericardial effusions.

Pectasides D, Stewart S, Courtenay-Luck N, Rampling R, Munro AJ, Krausz T, Dhokia B, Snook D, Hooker G, Durbin H, et al.

Br J Cancer. 1986 Jun;53(6):727-32.

34.

Antibody guided irradiation of brain glioma by arterial infusion of radioactive monoclonal antibody against epidermal growth factor receptor and blood group A antigen.

Epenetos AA, Courtenay-Luck N, Pickering D, Hooker G, Durbin H, Lavender JP, McKenzie CG.

Br Med J (Clin Res Ed). 1985 May 18;290(6480):1463-6.

35.

Signalling mitogenesis in 3T3 cells: role of monovalent ion fluxes and cyclic nucleotides.

Rozengurt E, Courtenay-Luck N.

Biosci Rep. 1982 Aug;2(8):589-95.

PMID:
6291663
36.

Cyclic AMP: a mitogenic signal for Swiss 3T3 cells.

Rozengurt E, Legg A, Strang G, Courtenay-Luck N.

Proc Natl Acad Sci U S A. 1981 Jul;78(7):4392-6.

Supplemental Content

Loading ...
Support Center